ClinicalTrials.gg
CompletedNCT03621670Updated Aug 20, 2026Results posted

Safety and Immunogenicity of GSK Meningococcal Group B Vaccine and 13-valent Pneumococcal Vaccine Administered Concomitantly With Routine Infant Vaccines to Healthy Infants

A Phase 3 interventional study of Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ) and Prevnar13 in Infections, Meningococcal, sponsored by GlaxoSmithKline. Completed at 57 sites in 2 countries. Open to participants aged 6 Weeks to 12 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-08-20.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,196
Allocation
Randomized
Ages
6 Weeks to 12 Weeks
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 71 studies in Meningococcal Infections by GlaxoSmithKline — none open to participants now, 1 under way, none of them phase 3. Meningococcal Infections · GlaxoSmithKline.

Enrollment
13th of 67
1,196 · median 613
Started
2018
with 3 others
Phase 3
34 of 71
none open now
Registered
64th of 71
by date

Among the 71 studies in Meningococcal Infections by GlaxoSmithKline, this one is the 13th largest by enrollment of the 67 interventional ones that give a count, is one of 4 that started in 2018, is one of 34 in phase 3, and was the 64th registered.

Meningococcal Infections

243 studies on the registry are indexed under Meningococcal Infections; 8 are open to participants now.

Browse Meningococcal Infections studies →

Open to participants now

None of the 71 studies in Meningococcal Infections by GlaxoSmithKline is open now. The open studies under Meningococcal Infections, anywhere →

Who these studies take

Of the 7 Meningococcal Infections studies recruiting now, 3 set no upper age limit and 4 stop at 75 or younger; 4 take children under 18; 6 take healthy volunteers.

This study: 6 Weeks to 12 Weeks · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 71 studies in Meningococcal Infections by GlaxoSmithKline as a file.
02

Study summary

The purpose of this study is to evaluate the safety and immunogenicity of Bexsero (meningococcal group B vaccine-rMenB+OMV NZ) in North American infants 6 weeks through 12 weeks of age, when administered concomitantly with Pneumococcal conjugate vaccine (PCV 13) and other recommended routine infant vaccinesv(RIV).

Read the detailed description

This study is divided into three timepoints:

Epoch 1 - Primary: Day 1 to Day 301 Epoch 2 - Secondary: Day 301 to Day 331 Epoch 3 - Safety follow-up: Day 331 to the end of the study (Day 481 or Day 661). For participants who have not yet reached the 6-month safety follow-up after their last dose at the time Protocol Amendment 7 takes effect, visit 7 takes place on Day 481.

In addition to receiving the study vaccines, infants also receive non-study vaccines such as Diphtheria, tetanus toxoids and acellular pertussis adsorbed vaccine (DTPa, Infanrix) and Haemophilus influenzae type b Conjugate Vaccine (Hib, Hiberix) to minimize disruption to the standard infant vaccination schedule caused by participation in this study.

Participants receive rMenB+OMV NZ (Bexsero) concomitantly with PCV13 (Prevnar13) and other routine infant vaccines (Pediarix, Hiberix, Rotarix, M-M-R II, Varivax) at 2, 4, 6, and 12 months of age. Participants who have received three PCV13 doses before 12 months of age but have not yet received their fourth booster dose receive either PCV13 or PCV20 at 12 months of age (Visit 5).

03

Conditions studied

  • Infections, Meningococcal

Keywords

  • Meningitis
  • Immune response
  • Sufficiency
  • Neisseria meningitides
  • Bexsero
04

Who can participate

Ages eligible
6 Weeks to 12 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

All subjects must satisfy all the following criteria at study entry:

  • Subjects' parent(s)/Legally Acceptable Representative(s) [LAR(s)] who, in the opinion of the investigator, can and will comply, with the requirements of the protocol (e.g. completion of the eDiary, return for follow-up visits).
  • Written obtained from the parent(s)/LAR(s) of the subject prior to performing any study specific procedure.
  • A male or female between, and including, 42 and 84 days of age (i.e., 6 through 12 weeks) at the time of the 1st vaccination.
  • Healthy subjects as established by medical history and clinical examination before entering into the study.
  • Born full-term (i.e. after a gestation period of ≥ 38 weeks).

Exclusion criteria

Exclusion Criteria:

If any exclusion criterion applies, the subject must not be included in the study:

  • Child in care

Each subject must not have:

  • Progressive, unstable or uncontrolled clinical conditions.
  • , including allergy to any component of vaccines, medicinal product or medical equipment whose use is foreseen in this study.
  • Hypersensitivity to latex.
  • Clinical conditions representing a to intramuscular vaccination and blood draws.
  • Abnormal function of the immune system resulting from:

    • Clinical conditions.
    • Systemic administration of (PO/IV/IM) for more than 14 consecutive days from birth.
    • Administration of antineoplastic and immunomodulating agents or radiotherapy for any duration from birth.
    • disorders (including, but not limited to: blood, endocrine, hepatic, muscular, nervous system or skin autoimmune disorders; lupus erythematosus and associated conditions; rheumatoid arthritis and associated conditions; scleroderma and associated disorders) or immunodeficiency syndromes (including, but not limited to: acquired immunodeficiency syndromes and primary immunodeficiency syndromes).
  • Received immunoglobulins or any blood products from birth.
  • Received an or non-registered medicinal product from birth.
  • Any other clinical condition that, in the opinion of the investigator, might pose additional risk to the subject due to participation in the study.
  • Neuroinflammatory disorders (including but not limited to: demyelinating disorders, encephalitis or myelitis of any origin), congenital and peripartum neurological conditions, encephalopathies, seizures (including all subtypes such as: absence seizures, generalised tonic-clonic seizures, partial complex seizures, partial simple seizures or febrile convulsions).
  • Congenital or peripartum disorders resulting in a chronic condition (including but not limited to: chromosomal abnormalities, cerebral palsy, metabolism or synthesis disorders, cardiac disorders).
  • Study personnel as an immediate family or household member.
  • Current or previous, confirmed or suspected disease caused by N. meningitidis
  • Household contact with and/or intimate exposure from birth to an individual with laboratory confirmed N. meningitidis and/or Streptococcus pneumoniae infection or colonization.
  • Previous administration of meningococcal B or pneumococcal vaccine at any time prior to .
  • Received a dose of DTPa--IPV, HRV, MMR, VV and/or Hib at any time prior to informed consent. Receipt of one dose of HBV up to 4 weeks prior to informed con-sent is allowed.
  • Serious chronic illness.
  • Uncorrected congenital malformation (such as Meckel's diverticulum) of the gastrointestinal tract that would predispose for Intussusception (IS).
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,196 participants (actual)

Study arms

  • Experimental
    MenB+PCV Group

    Infant participants received rMenB+OMV NZ (Bexsero) along with PCV13 (Prevnar 13), Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by rMenB+OMV NZ, PCV13, Pediarix and Hiberix on Day 121 and rMenB+OMV NZ, PCV13/PCV20, M-M-R II and Varivax on Day 301.

    Biological: Bexsero (GSK Biologicals' Meningococcal group-B vaccine/ rMenB+OMV NZ) · Biological: Prevnar13 · Biological: Pediarix · Biological: Hiberix · Biological: Rotarix · Biological: M-M-R II · Biological: Varivax · Biological: Prevnar 20

  • Placebo comparator
    Placebo+PCV Group

    Infant participants received PCV13 along with placebo, Pediarix, Hiberix and Rotarix on Day 1 and Day 61 followed by PCV13, Placebo, Pediarix and Hiberix on Day 121 and PCV13/PCV20, Placebo M-M-R II and Varivax on Day 301.

    Biological: Prevnar13 · Biological: Pediarix · Biological: Hiberix · Biological: Rotarix · Biological: M-M-R II · Biological: Varivax · Biological: Placebo (saline water) · Biological: Prevnar 20

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1

    Assessed solicited administration site events include injection site tenderness (administration site pain), erythema (redness), swelling and induration. Any solicited administration site events = occurrence of the event regardless of intensity grade. Rotarix was administered orally; therefore, no administration site events were analyzed.

    Time frame: Day 1 to Day 7

  2. Number of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1

    Assessed systemic events include change in eating habits, sleepiness, vomiting, diarrhea, irritability, persistent crying, and fever, defined as body temperature greater than or equal to (≥)38.0°C/100.4°F. Any solicited systemic events = occurrence of the event regardless of intensity grade.

    Time frame: Day 1 to Day 7

  3. Number of Participants Reporting Any Solicited Administration Site Events After the Second Vaccination Administered at Day 61

    Rotarix was administered orally; therefore, no administration site events were analyzed.

    Time frame: Day 61 to Day 67

  4. Number of Participants Reporting Any Solicited Systemic Events After the Second Vaccination Administered at Day 61

    Time frame: Day 61 to Day 67

  5. Number of Participants Reporting Any Solicited Administration Site Events After the Third Vaccination Administered at Day 121

    Time frame: Day 121 to Day 127

  6. Number of Participants Reporting Any Solicited Systemic Events After the Third Vaccination Administered at Day 121

    Time frame: Day 121 to Day 127

  7. Number of Participants Reporting Any Solicited Administration Site Events After the Fourth Vaccination Administered at Day 301

    Time frame: Day 301 to Day 307

  8. Number of Participants Reporting Any Solicited Systemic Events After the Fourth Vaccination Administered at Day 301

    Time frame: Day 301 to Day 307

  9. Number of Participants With Any Solicited Systemic AEs During the 30 Days After the Fourth Vaccination at Day 301

    Systemic events assessed included rash, parotid/salivary gland swelling, and fever. These systemic adverse events were recorded for 30 days following MMR and VV vaccine administration. Any solicited systemic events = occurrence of the event regardless of intensity grade.

    Time frame: Day 301 to Day 330

  10. Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1

    An unsolicited AEs is an AE that is not solicited using a subject diary and that is spontaneously communicated by the parent(s)/LAR(s) who has signed the informed consent or a solicited local or systemic AE that continues beyond the solicited period after vaccination. Any = occurrence of the event regardless of the intensity grade.

    Time frame: Day 1 to Day 30

  11. Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61

    Time frame: Day 61 to Day 90

  12. Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121

    Time frame: Day 121 to Day 150

  13. Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301

    Time frame: Day 301 to Day 330

  14. Number of Participants Reporting Any SAEs, AEs Leading to Withdrawal, AESIs and MAAEs

    An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization and that results in disability/incapacity. An AE leading to withdrawal includes any AEs/SAEs collected and recorded from the time of the 1st receipt of study vaccines until study end which are identified as reasons for withdrawal of the participant from the study. AESIs are pre-defined (serious or non-serious) AEs of scientific and medical concern specific to the product or program which might warrant further investigation in order to characterize and understand it. MAAEs includes any AEs that required hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.

    Time frame: Day 1 up to study end (Day 481 for participants who have not reached 6-month follow-up at the time of Protocol Amendment 7; Day 661 for all others)

  15. Percentage of Participants With Human Serum Bactericidal Assay (hSBA) Antibody Titers >= Lower Limit of Quantitation (LLOQ) for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4) and M13520 (NHBA)

    Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 60% for each of the M14459, 96217, NZ98/254, M13520 test strain. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 151 (1 month after the third vaccination)

  16. Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)

    The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 50% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 151 (1 month after the third vaccination)

  17. Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA) and >= 16 for Strain 96217

    Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥75% for each of the M14459, 96217, NZ98/254, M13520 test strains. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 331 (1 month after the fourth vaccination)

  18. Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)

    The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥65% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 331 (1 month after the fourth vaccination)

  19. Adjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third Vaccination

    The immune response to PCV13 is evaluated by measuring IgG levels using electrochemiluminescence (ECL) assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the third vaccination.

    Time frame: At Day 151 (1 month after the third vaccination)

Secondary outcomes

  1. Adjusted GMCs of IgG Antibodies Against 13 PCV13 Antigens at 1 Month After the Fourth Vaccination Administered at Day 301

    The immune response to PCV13 is evaluated by measuring IgG levels using ECL assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the 4th vaccination.

    Time frame: At Day 331 (1 month after the fourth vaccination)

  2. Percentage of Participants With Serum Pneumococcal Anti-capsular Polysaccharide IgG >= 0.35 μg/mL

    The immune response to PCV13 is evaluated by measuring the percentage of participants with serum IgG concentrations ≥ 0.35 μg/mL for each of the 13 PCV13 antigens at 1 month after the third and fourth vaccinations.

    Time frame: At Day 151 (1 month after the third vaccination) and Day 331 (1 month after the fourth vaccination)

  3. Adjusted GMCs Against 3 Pertussis Antigens (Pertussis Toxin [PT], Pertactin [PRN], Filamentous Hemagglutinin [FHA])

    The immune response to DTaP-HBV-IPV (Pediarix) vaccine is evaluated. IgG concentrations for pertussis antigens (PT, FHA, PRN) are measured at 1 month after the third vaccination and are expressed as international units per millilitre (IU/mL).

    Time frame: At Day 151 (1 month after the third vaccination)

  4. Percentage of Participants With Antibodies Concentrations Against Hepatitis B Surface Antigen (AntiHBsAg) >= 10 mIU/mL

    The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Hepatitis B (HepB) antigens are measured at 1 month after the third vaccination.

    Time frame: At Day 151 (1 month after the third vaccination)

  5. Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 0.1 IU/mL

    The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for diphtheria (D) and tetanus (T) were measured at 1 month after the third vaccination.

    Time frame: At Day 151 (1 month after the third vaccination)

  6. Percentage of Participants With Anti-polyribosyl-ribitol Phosphate (PRP) Concentration >= 0.15 µg/mL and >= 1 µg/mL

    The immune response to Hib vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Haemophilus influenzae type b (Hib) are measured at 1 month after the third vaccination.

    Time frame: At Day 151 (1 month after the third vaccination)

  7. Adjusted GMCs for Anti-measles Antibodies

    The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for measles antigens are measured using adjusted GMCs at 1 month after fourth vaccination and are expressed as milli-International Units per milliliter (mIU/mL).

    Time frame: At Day 331 (1 month after the fourth vaccination)

  8. Adjusted GMCs for Anti-mumps Antibodies

    The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for mumps antigens are measured using adjusted GMCs at 1 month after fourth vaccination.

    Time frame: At Day 331 (1 month after the fourth vaccination)

  9. Adjusted GMCs for Anti-rubella Antibodies

    The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for rubella antigens are measured using adjusted GMCs at 1 month after fourth vaccination.

    Time frame: At Day 331 (1 month after the fourth vaccination)

  10. Adjusted GMCs for Anti-Varicella (VV) Antibodies

    The immune response to varicella (VV) vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for varicella antigens are measured using GMCs at 1 month after fourth vaccination.

    Time frame: At Day 331 (1 month after the fourth vaccination)

  11. Percentage of Participants With hSBA Antibody Titers >= 5, >= 8 and >=16 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 151 (1 month after the third vaccination)

  12. Percentage of Participants With hSBA Antibody Titers >= 5 and >= 8 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 301 (6 months after third vaccination)

  13. Percentage of Participants With hSBA Antibody Titers >= 5 for Each of the Serogroup B Test Strain M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 331 (1 month after the fourth vaccination)

  14. hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 151 (1 month after the third vaccination), Day 301 (6 months after the third vaccination), and Day 331 (1 month after the fourth vaccination)

  15. hSBA Geometric Mean Ratios (GMRs) Over Pre Fourth Vaccination Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 331 (1 month after the fourth vaccination) compared to Day 301 (pre-fourth vaccination)

  16. Percentage of Participants With hSBA Antibody Titers >= LLOQ for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 301 (6 months after the third vaccination) and Day 331 (1 month after the fourth vaccination)

  17. Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

    A 4-fold rise in hSBA titers is defined as - if pre-vaccination titer \<Limit of Detection (LOD), then a post-vaccination titer \>= 4 times the LOD or \>= LLOQ, whichever is greater; - if pre-vaccination titer is \>= LOD but \<LLOQ, then a post-vaccination titer \>= 4 times the LLOQ; - if pre-vaccination titer is \>= LLOQ, then a post-vaccination titer \>= 4 times the pre-vaccination titer, where pre-vaccination titer=pre-4th dose titers (Day 301). This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

    Time frame: At Day 331 (1 month after the fourth vaccination) relative to Day 301 (pre-fourth vaccination)

  18. Percentage of Participants With Anti-HBs Antibody Concentrations >= 100 mIU/mL

    Time frame: At Day 151 (1 month after the third vaccination)

  19. GMCs for Anti-HBsAg Antibodies

    Time frame: At Day 151 (1 month after the third vaccination)

  20. Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 1 IU/mL

    Time frame: At Day 151 (1 month after the third vaccination)

  21. GMCs for Anti-diphtheria and Anti-tetanus Antibodies

    Time frame: At Day 151 (1 month after the third vaccination)

  22. Percentage of Participants With Anti-polio Type 1, 2 and 3 Neutralization Antibody Titers >= 8

    Time frame: At Day 151 (1 month after the third vaccination)

  23. Percentage of Participants With Seroresponse for Anti-Varicella (VV), Anti-measles Virus, Anti-mumps Virus and Anti-rubella Virus Antibodies

    Seroresponse is defined as post-vaccination anti-VZV virus, anti-measles virus, anti-mumps virus and anti-rubella virus antibody concentration \>= a protective threshold among participants who were seronegative (antibody concentration \< assay cut-off) before vaccination.

    Time frame: At Day 331 (1 month after the fourth vaccination)

07

Results

Posted Feb 10, 2026

Participant flow

Participant flow — Overall Study
MilestoneMenB+PCV GroupPlacebo+PCV Group
Started781403
Completed642326
Not completed13977
Withdrew: Adverse event31
Withdrew: Lost to follow-up3225
Withdrew: Consent withdrawal not due to aes5418
Withdrew: Migrated / moved from the study area2112
Withdrew: Not willing / not able to be contacted913
Withdrew: Other135
Withdrew: Protocol deviation73

Outcome measures

PrimaryNumber of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1

Assessed solicited administration site events include injection site tenderness (administration site pain), erythema (redness), swelling and induration. Any solicited administration site events = occurrence of the event regardless of intensity grade. Rotarix was administered orally; therefore, no administration site events were analyzed.

Time frame:
Day 1 to Day 7
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Administration Site Events After the First Vaccination Administered at Day 1
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Erythema, Bexsero156—
Erythema, Prevnar 1310039
Erythema, Placebo—25
Erythema, Pediarix7232
Erythema, Hiberix7417
Induration, Bexsero204—
Induration, Prevnar 1312767
Induration, Placebo—22
Induration, Pediarix7034
Induration, Hiberix7720
Swelling, Bexsero132—
Swelling, Prevnar 137734
Swelling, Placebo—21
Swelling, Pediarix5321
Swelling, Hiberix5412
Tenderness, Bexsero352—
Tenderness, Prevnar 13310107
Tenderness, Placebo081
Tenderness, Pediarix27092
Tenderness, Hiberix28474
PrimaryNumber of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1

Assessed systemic events include change in eating habits, sleepiness, vomiting, diarrhea, irritability, persistent crying, and fever, defined as body temperature greater than or equal to (≥)38.0°C/100.4°F. Any solicited systemic events = occurrence of the event regardless of intensity grade.

Time frame:
Day 1 to Day 7
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events After the First Vaccination Administered at Day 1
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Change in eating habits329122
Diarrhea17384
Irritability601242
Persistent crying24889
Sleepiness560246
Vomiting17679
Fever25234
PrimaryNumber of Participants Reporting Any Solicited Administration Site Events After the Second Vaccination Administered at Day 61

Rotarix was administered orally; therefore, no administration site events were analyzed.

Time frame:
Day 61 to Day 67
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Administration Site Events After the Second Vaccination Administered at Day 61
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Erythema, Bexsero200—
Erythema, Prevnar 1312962
Erythema, Placebo—44
Erythema, Pediarix9954
Erythema, Hiberix8641
Induration, Bexsero213—
Induration, Prevnar 1314263
Induration, Placebo—32
Induration, Pediarix10955
Induration, Hiberix8032
Swelling, Bexsero112—
Swelling, Prevnar 137438
Swelling, Placebo—19
Swelling, Pediarix5233
Tenderness, Bexsero269—
Swelling, Hiberix4917
Tenderness, Prevnar 1322781
Tenderness, Placebo065
Tenderness, Pediarix20167
Tenderness, Hiberix20752
PrimaryNumber of Participants Reporting Any Solicited Systemic Events After the Second Vaccination Administered at Day 61
Time frame:
Day 61 to Day 67
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events After the Second Vaccination Administered at Day 61
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Change in eating habits23890
Diarrhea11966
Irritability514215
Persistent crying20973
Sleepiness455183
Vomiting10449
Fever26964
PrimaryNumber of Participants Reporting Any Solicited Administration Site Events After the Third Vaccination Administered at Day 121
Time frame:
Day 121 to Day 127
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Administration Site Events After the Third Vaccination Administered at Day 121
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Erythema, Bexsero181—
Erythema, Prevnar 1312771
Erythema, Placebo—43
Erythema, Pediarix11465
Erythema, Hiberix9738
Induration, Bexsero187—
Induration, Prevnar 1312860
Induration, Placebo—26
Induration, Pediarix12470
Induration, Hiberix8628
Swelling, Bexsero103—
Swelling, Prevnar 136739
Swelling, Placebo—13
Swelling, Pediarix5528
Swelling, Hiberix368
Tenderness, Bexsero244—
Tenderness, Prevnar 1321066
Tenderness, Placebo—52
Tenderness, Pediarix18858
Tenderness, Hiberix19445
PrimaryNumber of Participants Reporting Any Solicited Systemic Events After the Third Vaccination Administered at Day 121
Time frame:
Day 121 to Day 127
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events After the Third Vaccination Administered at Day 121
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Change in eating habits20594
Diarrhea8744
Irritability454179
Persistent crying15159
Sleepiness326142
Vomiting8846
Fever21655
PrimaryNumber of Participants Reporting Any Solicited Administration Site Events After the Fourth Vaccination Administered at Day 301
Time frame:
Day 301 to Day 307
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Administration Site Events After the Fourth Vaccination Administered at Day 301
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Erythema, Bexsero180—
Erythema, Prevnar 13/2011937
Erythema, Placebo—25
Erythema, MMR II6424
Erythema, Varivax6220
Induration, Bexsero179—
Induration, Prevnar 13/2010932
Induration, Placebo—24
Induration, MMR II4617
Induration, Varivax3815
Swelling, Bexsero91—
Swelling, Prevnar 13/205218
Swelling, Placebo—8
Swelling, MMR II2612
Swelling, Varivax239
Tenderness, Bexsero223—
Tenderness, Prevnar 13/2018135
Tenderness, Placebo—31
Tenderness, MMR II13028
Tenderness, Varivax11927
PrimaryNumber of Participants Reporting Any Solicited Systemic Events After the Fourth Vaccination Administered at Day 301
Time frame:
Day 301 to Day 307
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Solicited Systemic Events After the Fourth Vaccination Administered at Day 301
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Change in eating habits21975
Diarrhea8540
Irritability401153
Persistent crying11529
Rash7130
Sleepiness27396
Vomiting6032
Fever11822
PrimaryNumber of Participants With Any Solicited Systemic AEs During the 30 Days After the Fourth Vaccination at Day 301

Systemic events assessed included rash, parotid/salivary gland swelling, and fever. These systemic adverse events were recorded for 30 days following MMR and VV vaccine administration. Any solicited systemic events = occurrence of the event regardless of intensity grade.

Time frame:
Day 301 to Day 330
Reported as:
Count of participants · Participants
Number of Participants With Any Solicited Systemic AEs During the 30 Days After the Fourth Vaccination at Day 301
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Parotid/Salivary gland swelling2017
Rash20695
Fever19770
PrimaryNumber of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1

An unsolicited AEs is an AE that is not solicited using a subject diary and that is spontaneously communicated by the parent(s)/LAR(s) who has signed the informed consent or a solicited local or systemic AE that continues beyond the solicited period after vaccination. Any = occurrence of the event regardless of the intensity grade.

Time frame:
Day 1 to Day 30
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Number of Participants Reporting Any Unsolicited Adverse Events (AEs) After the First Vaccination Administered at Day 1214103
PrimaryNumber of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61
Time frame:
Day 61 to Day 90
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Number of Participants Reporting Any Unsolicited AEs After the Second Vaccination Administered at Day 61225119
PrimaryNumber of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121
Time frame:
Day 121 to Day 150
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Number of Participants Reporting Any Unsolicted AEs After the Third Vaccination Administered at Day 121230120
PrimaryNumber of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301
Time frame:
Day 301 to Day 330
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301
ParticipantsMenB+PCV GroupPlacebo+PCV Group
Number of Participants Reporting Any Unsolicited AEs After the Fourth Vaccination Administered at Day 301248144
PrimaryNumber of Participants Reporting Any SAEs, AEs Leading to Withdrawal, AESIs and MAAEs

An SAE is any untoward medical occurrence that results in death, is life-threatening, requires hospitalization or prolongation of existing hospitalization and that results in disability/incapacity. An AE leading to withdrawal includes any AEs/SAEs collected and recorded from the time of the 1st receipt of study vaccines until study end which are identified as reasons for withdrawal of the participant from the study. AESIs are pre-defined (serious or non-serious) AEs of scientific and medical concern specific to the product or program which might warrant further investigation in order to characterize and understand it. MAAEs includes any AEs that required hospitalization, or an otherwise unscheduled visit to or from medical personnel for any reason, including emergency room visits.

Time frame:
Day 1 up to study end (Day 481 for participants who have not reached 6-month follow-up at the time of Protocol Amendment 7; Day 661 for all others)
Reported as:
Count of participants · Participants
Number of Participants Reporting Any SAEs, AEs Leading to Withdrawal, AESIs and MAAEs
ParticipantsMenB+PCV GroupPlacebo+PCV Group
AEs leading to withdrawal31
SAEs3519
AESIs63
MAAEs626329
PrimaryPercentage of Participants With Human Serum Bactericidal Assay (hSBA) Antibody Titers >= Lower Limit of Quantitation (LLOQ) for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4) and M13520 (NHBA)

Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 60% for each of the M14459, 96217, NZ98/254, M13520 test strain. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With Human Serum Bactericidal Assay (hSBA) Antibody Titers >= Lower Limit of Quantitation (LLOQ) for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4) and M13520 (NHBA)
Percentage of participantsMenB+PCV Group
M14459 (fHbp)92.2 (88.6 to 94.9)
96217 (NadA)99.4 (97.9 to 99.9)
NZ98/254 (PorA)73.5 (68.2 to 78.3)
M13520 (NHBA)53.0 (47.3 to 58.6)
PrimaryPercentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)

The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the third vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ LLOQ is ≥ 50% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)
Percentage of participantsMenB+PCV Group
Percentage of Participants With hSBA Titers >= LLOQ Against All Serogroup B Test Strains Combined (Composite Response)42.7 (37.0 to 48.6)
PrimaryPercentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA) and >= 16 for Strain 96217

Serum bactericidal activity is assessed using human complement (hSBA) against Neisseria meningitidis serogroup B test strains: M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA). The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥75% for each of the M14459, 96217, NZ98/254, M13520 test strains. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 331 (1 month after the fourth vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp); 96217 (NadA); NZ98/254 (PorA P1.4); M13520 (NHBA) and >= 16 for Strain 96217
Percentage of participantsMenB+PCV Group
M14459 (fHbp)89.0 (85.8 to 91.7)
96217 (NadA)99.6 (98.5 to 100)
NZ98/254 (PorA P1.4)83.2 (79.4 to 86.5)
M13520 (NHBA)76.6 (72.5 to 80.4)
PrimaryPercentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)

The immune response to the rMenB+OMV NZ vaccine is assessed by measuring serum bactericidal activity using hSBA against four Neisseria meningitidis serogroup B test strains: M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA). The composite response is defined as the percentage of participants with hSBA titers ≥ Lower Limit of Quantitation (LLOQ) across all four strains combined. The sufficiency of the immune response to rMenB+OMV NZ at one month after the 4th vaccination was to be demonstrated if the lower confidence limit for the percentage of participants achieving hSBA titers ≥ 8 (for strains M14459, NZ98/254, M13520) and ≥16 (for strain 96217) is ≥65% for all strains combined. This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 331 (1 month after the fourth vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)
Percentage of participantsMenB+PCV Group
Percentage of Participants With hSBA Antibody Titers >= 8 for Strains M14459 (fHbp), NZ98/254 (PorA P1.4), and M13520 (NHBA) and >= 16 for Strain 96217 (NadA) (Composite Response Across All Strains)63.2 (58.5 to 67.7)
PrimaryAdjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third Vaccination

The immune response to PCV13 is evaluated by measuring IgG levels using electrochemiluminescence (ECL) assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the third vaccination.

Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Geometric mean · Microgram per milliliter(µg/mL)
Adjusted Geometric Mean Concentrations (GMCs) of Immunoglobubin (IgG) Antibodies Against 13 PCV13 Antigens at 1 Month After Third Vaccination
Microgram per milliliter(µg/mL)MenB+PCV GroupPlacebo+PCV Group
Serotype 11.6 (1.4 to 1.9)1.5 (1.3 to 1.8)
Serotype 30.5 (0.4 to 0.6)0.5 (0.4 to 0.6)
Serotype 41.1 (0.9 to 1.3)1.1 (1.0 to 1.3)
Serotype 51.0 (0.8 to 1.2)1.0 (0.8 to 1.2)
Serotype 62.4 (2.0 to 2.8)2.5 (2.1 to 2.9)
Serotype 6B1.5 (1.1 to 1.9)1.8 (1.4 to 2.3)
Serotype 7F2.8 (2.4 to 3.3)2.9 (2.5 to 3.3)
Serotype 9V1.3 (1.1 to 1.6)1.4 (1.2 to 1.6)
Serotype 145.9 (4.7 to 7.4)5.8 (4.8 to 7.2)
Serotype 18C1.5 (1.3 to 1.8)1.5 (1.3 to 1.8)
Serotype 19A1.7 (1.4 to 2.0)1.8 (1.6 to 2.2)
Serotype 19F2.5 (2.1 to 2.9)2.5 (2.2 to 2.9)
Serotype 23F0.9 (0.7 to 1.1)1.0 (0.8 to 1.2)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 1.05 · 98.3% CI 0.90 to 1.23GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way Analysis of Variance (ANOVA), accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.90 · 98.3% CI 0.77 to 1.06GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.98 · 98.3% CI 0.84 to 1.15GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 1.03 · 98.3% CI 0.86 to 1.22GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.95 · 98.3% CI 0.81 to 1.11GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.80 · 98.3% CI 0.63 to 1.02GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.98 · 98.3% CI 0.85 to 1.12GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.94 · 98.3% CI 0.80 to 1.12GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 1.01 · 98.3% CI 0.82 to 1.24GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 1.00 · 98.3% CI 0.85 to 1.18GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.91 · 98.3% CI 0.77 to 1.06GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.99 · 98.3% CI 0.86 to 1.14GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.87 · 98.3% CI 0.73 to 1.05GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
SecondaryAdjusted GMCs of IgG Antibodies Against 13 PCV13 Antigens at 1 Month After the Fourth Vaccination Administered at Day 301

The immune response to PCV13 is evaluated by measuring IgG levels using ECL assay. Adjusted GMCs are assessed for each of the 13 PCV13 antigens at 1 month after the 4th vaccination.

Time frame:
At Day 331 (1 month after the fourth vaccination)
Reported as:
Geometric mean · µg/mL
Adjusted GMCs of IgG Antibodies Against 13 PCV13 Antigens at 1 Month After the Fourth Vaccination Administered at Day 301
µg/mLMenB+PCV GroupPlacebo+PCV Group
Serotype 11.8 (1.5 to 2.1)1.8 (1.6 to 2.1)
Serotype 30.5 (0.4 to 0.6)0.5 (0.5 to 0.6)
Serotype 41.5 (1.2 to 1.8)1.7 (1.4 to 2.0)
Serotype 51.8 (1.5 to 2.1)1.8 (1.6 to 2.1)
Serotype 65.2 (4.4 to 6.1)6.0 (5.2 to 7.0)
Serotype 6B4.7 (3.9 to 5.6)5.4 (4.6 to 6.4)
Serotype 7F3.7 (3.2 to 4.4)4.6 (4.0 to 5.3)
Serotype 9V2.3 (2.0 to 2.8)2.6 (2.2 to 3.1)
Serotype 147.0 (5.8 to 8.4)7.1 (6.0 to 8.4)
Serotype 18C2.0 (1.7 to 2.4)2.2 (1.9 to 2.6)
Serotype 19A4.5 (3.8 to 5.3)5.5 (4.7 to 6.4)
Serotype 19F4.8 (4.1 to 5.7)5.0 (4.3 to 5.9)
Serotype 23F1.9 (1.5 to 2.3)1.9 (1.6 to 2.3)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.95 · 95% CI 0.82 to 1.11GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.90 · 95% CI 0.79 to 1.03GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.90 · 95% CI 0.77 to 1.07GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.97 · 95% CI 0.83 to 1.12GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.86 · 95% CI 0.74 to 0.99GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.86 · 95% CI 0.73 to 1.02GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.81 · 95% CI 0.70 to 0.93GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.90 · 95% CI 0.77 to 1.06GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.99 · 95% CI 0.83 to 1.17GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.89 · 95% CI 0.76 to 1.04GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.82 · 95% CI 0.71 to 0.95GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.96 · 95% CI 0.83 to 1.12GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.97 · 95% CI 0.82 to 1.16GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
SecondaryPercentage of Participants With Serum Pneumococcal Anti-capsular Polysaccharide IgG >= 0.35 μg/mL

The immune response to PCV13 is evaluated by measuring the percentage of participants with serum IgG concentrations ≥ 0.35 μg/mL for each of the 13 PCV13 antigens at 1 month after the third and fourth vaccinations.

Time frame:
At Day 151 (1 month after the third vaccination) and Day 331 (1 month after the fourth vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serum Pneumococcal Anti-capsular Polysaccharide IgG >= 0.35 μg/mL
Percentage of participantsMenB+PCV GroupPlacebo+PCV Group
Serotype 1, At Day 15199.2 (97.1 to 99.9)97.1 (94.4 to 98.7)
Serotype 1, At Day 33198.7 (96.2 to 99.7)97.1 (94.1 to 98.8)
Serotype 3, At Day 15159.8 (53.4 to 66.0)61.5 (55.5 to 67.3)
Serotype 3, At Day 33163.6 (56.9 to 69.8)69.5 (63.2 to 75.2)
Serotype 4, At Day 15194.3 (90.6 to 96.8)96.0 (93.0 to 98.0)
Serotype 4, At Day 33197.8 (94.9 to 99.3)96.7 (93.5 to 98.6)
Serotype 5, At Day 15191.0 (86.7 to 94.3)87.4 (82.9 to 91.1)
Serotype 5, At Day 33196.0 (92.5 to 98.2)98.8 (96.4 to 99.7)
Serotype 6, At Day 15199.2 (97.1 to 99.9)99.6 (98.0 to 100)
Serotype 6, At Day 331100 (98.4 to 100)99.6 (97.7 to 100)
Serotype 6B, At Day 15189.8 (85.2 to 93.3)92.4 (88.7 to 95.3)
Serotype 6B, At Day 331100 (98.4 to 100)99.6 (97.7 to 100)
Serotype 7F, At Day 15199.6 (97.7 to 100)100 (98.7 to 100)
Serotype 7F, At Day 33199.6 (97.5 to 100)100 (98.5 to 100)
Serotype 9V, At Day 15195.1 (91.6 to 97.4)93.2 (89.5 to 95.8)
Serotype 9V, At Day 33198.7 (96.1 to 99.7)98.8 (96.4 to 99.7)
Serotype 14, At Day 15198.0 (95.3 to 99.3)98.6 (96.4 to 99.6)
Serotype 14, At Day 331100 (98.4 to 100)100 (98.5 to 100)
Serotype 18C, At Day 15197.5 (94.7 to 99.1)96.8 (93.9 to 98.5)
Serotype 18C, At Day 33199.1 (96.8 to 99.9)99.2 (97.0 to 99.9)
Serotype 19A, At Day 15196.7 (93.6 to 98.6)98.6 (96.4 to 99.6)
Serotype 19A, At Day 331100 (98.4 to 100)99.6 (97.7 to 100)
Serotype 19F, At Day 15199.6 (97.7 to 100)100 (98.7 to 100)
Serotype 19F, At Day 331100 (98.4 to 100)100 (98.5 to 100)
Serotype 23F, At Day 15187.3 (82.5 to 91.2)87.0 (82.5 to 90.7)
Serotype 23F, At Day 33197.3 (94.3 to 99.0)97.1 (94.1 to 98.8)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 2.06 · 95% CI -0.38 to 4.87The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 1.58 · 95% CI -1.28 to 4.74The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -1.67 · 95% CI -10.07 to 6.70The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -5.90 · 95% CI -14.45 to 2.69The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -1.78 · 95% CI -5.87 to 1.97The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 1.11 · 95% CI -2.17 to 4.51The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 3.57 · 95% CI -1.86 to 8.96The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -2.75 · 95% CI -6.33 to 0.16The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -0.46 · 95% CI -2.62 to 1.27The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.42 · 95% CI -1.27 to 2.33The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -2.69 · 95% CI -7.86 to 2.21The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.42 · 95% CI -1.27 to 2.33The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -0.41 · 95% CI -2.29 to 0.96The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -0.44 · 95% CI -2.48 to 1.14The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 1.92 · 95% CI -2.30 to 6.12The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -0.09 · 95% CI -2.76 to 2.44The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -0.61 · 95% CI -3.43 to 1.87The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.00 · 95% CI -1.68 to 1.58The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.78 · 95% CI -2.40 to 3.91The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -0.06 · 95% CI -2.44 to 2.20The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -1.84 · 95% CI -5.06 to 0.83The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.42 · 95% CI -1.27 to 2.33The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -0.41 · 95% CI -2.29 to 0.96The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.00 · 95% CI -1.68 to 1.58The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.29 · 95% CI -5.62 to 6.07The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.25 · 95% CI -3.13 to 3.58The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
SecondaryAdjusted GMCs Against 3 Pertussis Antigens (Pertussis Toxin [PT], Pertactin [PRN], Filamentous Hemagglutinin [FHA])

The immune response to DTaP-HBV-IPV (Pediarix) vaccine is evaluated. IgG concentrations for pertussis antigens (PT, FHA, PRN) are measured at 1 month after the third vaccination and are expressed as international units per millilitre (IU/mL).

Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Geometric mean · IU/mL
Adjusted GMCs Against 3 Pertussis Antigens (Pertussis Toxin [PT], Pertactin [PRN], Filamentous Hemagglutinin [FHA])
IU/mLMenB+PCV GroupPlacebo+PCV Group
PT50.3 (45.1 to 56.0)59.6 (53.2 to 66.8)
FHA106.7 (96.4 to 118.0)133.1 (119.5 to 148.2)
Pertactin41.7 (36.1 to 48.1)65.7 (56.4 to 76.4)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.84 · 95% CI 0.76 to 0.94GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.80 · 95% CI 0.73 to 0.88GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.63 · 95% CI 0.55 to 0.73GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
SecondaryPercentage of Participants With Antibodies Concentrations Against Hepatitis B Surface Antigen (AntiHBsAg) >= 10 mIU/mL

The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Hepatitis B (HepB) antigens are measured at 1 month after the third vaccination.

Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With Antibodies Concentrations Against Hepatitis B Surface Antigen (AntiHBsAg) >= 10 mIU/mL
Percentage of participantsMenB+PCV GroupPlacebo+PCV Group
Percentage of Participants With Antibodies Concentrations Against Hepatitis B Surface Antigen (AntiHBsAg) >= 10 mIU/mL100 (96.5 to 100)99.3 (96.0 to 100)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.72 · 95% CI -2.83 to 4.00The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
SecondaryPercentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 0.1 IU/mL

The immune response to DTaP-HBV-IPV vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for diphtheria (D) and tetanus (T) were measured at 1 month after the third vaccination.

Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 0.1 IU/mL
Percentage of participantsMenB+PCV GroupPlacebo+PCV Group
Tetanus Toxoid100 (98.4 to 100)100 (97.5 to 100)
Diphtheria Toxoid99.5 (97.5 to 100)100 (97.3 to 100)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.00 · 95% CI -1.69 to 2.62The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: -0.45 · 95% CI -2.53 to 2.30The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
SecondaryPercentage of Participants With Anti-polyribosyl-ribitol Phosphate (PRP) Concentration >= 0.15 µg/mL and >= 1 µg/mL

The immune response to Hib vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for Haemophilus influenzae type b (Hib) are measured at 1 month after the third vaccination.

Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-polyribosyl-ribitol Phosphate (PRP) Concentration >= 0.15 µg/mL and >= 1 µg/mL
Percentage of participantsMenB+PCV GroupPlacebo+PCV Group
>= 0.15 µg/mL98.3 (96.3 to 99.4)97.7 (95.1 to 99.2)
>= 1 µg/mL87.0 (83.0 to 90.4)84.1 (79.1 to 88.3)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 0.54 · 95% CI -1.79 to 3.32The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
  • MenB+PCV Group vs Placebo+PCV Group · Difference in percentage: 2.94 · 95% CI -2.63 to 8.78The 95% CI of the between MenB+PCV and Placebo+PCV group-difference has been derived using the method of Miettinen and Nurminen.
SecondaryAdjusted GMCs for Anti-measles Antibodies

The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for measles antigens are measured using adjusted GMCs at 1 month after fourth vaccination and are expressed as milli-International Units per milliliter (mIU/mL).

Time frame:
At Day 331 (1 month after the fourth vaccination)
Reported as:
Geometric mean · mIU/mL
Adjusted GMCs for Anti-measles Antibodies
mIU/mLMenB+PCV GroupPlacebo+PCV Group
Adjusted GMCs for Anti-measles Antibodies877.3 (743.7 to 1035.0)873.5 (732.2 to 1042.0)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 1.00 · 95% CI 0.86 to 1.17GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
SecondaryAdjusted GMCs for Anti-mumps Antibodies

The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for mumps antigens are measured using adjusted GMCs at 1 month after fourth vaccination.

Time frame:
At Day 331 (1 month after the fourth vaccination)
Reported as:
Geometric mean · Arbitrary Units per milliliter (AU/mL)
Adjusted GMCs for Anti-mumps Antibodies
Arbitrary Units per milliliter (AU/mL)MenB+PCV GroupPlacebo+PCV Group
Adjusted GMCs for Anti-mumps Antibodies744.5 (628.5 to 882.0)856.8 (715.0 to 1026.7)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 0.87 · 95% CI 0.74 to 1.02GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
SecondaryAdjusted GMCs for Anti-rubella Antibodies

The immune response to MMR vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for rubella antigens are measured using adjusted GMCs at 1 month after fourth vaccination.

Time frame:
At Day 331 (1 month after the fourth vaccination)
Reported as:
Geometric mean · IU/mL
Adjusted GMCs for Anti-rubella Antibodies
IU/mLMenB+PCV GroupPlacebo+PCV Group
Adjusted GMCs for Anti-rubella Antibodies57.7 (50.0 to 66.6)54.0 (46.3 to 63.0)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 1.07 · 95% CI 0.93 to 1.22GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
SecondaryAdjusted GMCs for Anti-Varicella (VV) Antibodies

The immune response to varicella (VV) vaccine administered with rMenB+OMV NZ and PCV13 is evaluated. IgG concentrations for varicella antigens are measured using GMCs at 1 month after fourth vaccination.

Time frame:
At Day 331 (1 month after the fourth vaccination)
Reported as:
Geometric mean · mIU/mL
Adjusted GMCs for Anti-Varicella (VV) Antibodies
mIU/mLMenB+PCV GroupPlacebo+PCV Group
Adjusted GMCs for Anti-Varicella (VV) Antibodies1283.8 (1137.4 to 1449.2)1208.9 (1060.5 to 1378.2)
Statistical analysis
  • MenB+PCV Group vs Placebo+PCV Group · Group gmc ratio: 1.06 · 95% CI 0.95 to 1.19GMCs and alpha-adjusted CIs were derived by exponentiating (base 10) the least squares means and 95% CI of log10-transformed antibody concentrations from a two-way ANOVA, accounting for vaccine-group and center effects.
SecondaryPercentage of Participants With hSBA Antibody Titers >= 5, >= 8 and >=16 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Antibody Titers >= 5, >= 8 and >=16 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
Percentage of participantsMenB+PCV Group
M14459 (fHbp), >= 592.2 (89.6 to 94.3)
M14459 (fHbp), >= 882.9 (79.4 to 86.0)
M14459 (fHbp), >= 1650.5 (46.2 to 54.8)
96217 (NadA), >= 599.6 (98.6 to 100)
96217 (NadA), >= 899.6 (98.6 to 100)
96217 (NadA), >= 1699.4 (98.3 to 99.9)
NZ98/254 (PorA P1.4), >= 577.7 (74.0 to 81.1)
NZ98/254 (PorA P1.4), >= 861.8 (57.6 to 65.9)
NZ98/254 (PorA P1.4), >= 1631.1 (27.2 to 35.1)
M13520 (NHBA), >= 560.4 (56.2 to 64.5)
M13520 (NHBA), >= 832.4 (28.5 to 36.4)
M13520 (NHBA), >= 169.4 (7.1 to 12.1)
SecondaryPercentage of Participants With hSBA Antibody Titers >= 5 and >= 8 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 301 (6 months after third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Antibody Titers >= 5 and >= 8 for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
Percentage of participantsMenB+PCV Group
M14459 (fHbp), >= 514.5 (11.6 to 17.9)
M14459 (fHbp), >= 84.8 (3.2 to 7.1)
96217 (NadA) >= 597.8 (96.1 to 98.9)
96217 (NadA), >= 896.4 (94.4 to 97.9)
NZ98/254 (PorA P1.4), >= 520.2 (16.8 to 23.8)
NZ98/254 (PorA P1.4), >= 812.2 (9.6 to 15.3)
M13520 (NHBA), >= 510.2 (7.8 to 13.1)
M13520 (NHBA) >= 85.9 (4.1 to 8.3)
SecondaryPercentage of Participants With hSBA Antibody Titers >= 5 for Each of the Serogroup B Test Strain M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 331 (1 month after the fourth vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Antibody Titers >= 5 for Each of the Serogroup B Test Strain M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
Percentage of participantsMenB+PCV Group
M14459 (fHbp), >= 594.5 (92.1 to 96.4)
96217 (NadA), >= 599.6 (98.5 to 99.9)
NZ98/254 (PorA P1.4), >= 589.6 (86.6 to 92.1)
M13520 (NHBA), >= 591.5 (88.7 to 93.8)
SecondaryhSBA Geometric Mean Titers (GMTs) Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 151 (1 month after the third vaccination), Day 301 (6 months after the third vaccination), and Day 331 (1 month after the fourth vaccination)
Reported as:
Geometric mean · Titer
hSBA Geometric Mean Titers (GMTs) Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
TiterMenB+PCV Group
M14459 (fHbp), Day 15115.1 (13.7 to 16.7)
M14459 (fHbp), Day 3013.0 (2.8 to 3.2)
M14459 (fHbp), Day 33124.3 (21.3 to 27.8)
96217 (NadA), Day 151488.2 (437.3 to 545.0)
96217 (NadA), Day 30189.1 (77.3 to 102.7)
96217 (NadA), Day 3311349.0 (1195.3 to 1522.5)
NZ98/254 (PorA P1.4), Day 15110.1 (8.9 to 11.4)
NZ98/254 (PorA P1.4), Day 3013.8 (3.5 to 4.0)
NZ98/254 (PorA P1.4), Day 33120.3 (17.3 to 23.7)
M13520 (NHBA), Day 1515.5 (5.0 to 6.0)
M13520 (NHBA), Day 3013.5 (3.3 to 3.7)
M13520 (NHBA), Day 33112.7 (11.2 to 14.4)
SecondaryhSBA Geometric Mean Ratios (GMRs) Over Pre Fourth Vaccination Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 331 (1 month after the fourth vaccination) compared to Day 301 (pre-fourth vaccination)
Reported as:
Geometric mean · Ratio
hSBA Geometric Mean Ratios (GMRs) Over Pre Fourth Vaccination Against Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
RatioMenB+PCV Group
M14459 (fHbp)8.7 (7.6 to 10.0)
96217 (NadA)17.4 (15.1 to 20.1)
NZ98/254 (PorA P1.4)5.5 (4.7 to 6.5)
M13520 (NHBA)3.9 (3.4 to 4.4)
SecondaryPercentage of Participants With hSBA Antibody Titers >= LLOQ for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

This immune response to the rMenB+OMV NZ vaccine only is evaluated, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 301 (6 months after the third vaccination) and Day 331 (1 month after the fourth vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Antibody Titers >= LLOQ for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
Percentage of participantsMenB+PCV Group
M14459 (fHbp), Day 30114.5 (11.6 to 17.9)
M14459 (fHbp), Day 33194.5 (92.1 to 96.4)
96217 (NadA), Day 30194.1 (91.6 to 96.0)
96217 (NadA), Day 33199.6 (98.5 to 99.9)
M13520 (NHBA), Day 3018.5 (6.3 to 11.2)
M13520 (NHBA), Day 33186.1 (82.8 to 89.0)
NZ98/254 (PorA P1.4), Day 30117.5 (14.4 to 21.0)
NZ98/254 (PorA P1.4), Day 33187.6 (84.4 to 90.3)
SecondaryPercentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)

A 4-fold rise in hSBA titers is defined as - if pre-vaccination titer \<Limit of Detection (LOD), then a post-vaccination titer \>= 4 times the LOD or \>= LLOQ, whichever is greater; - if pre-vaccination titer is \>= LOD but \<LLOQ, then a post-vaccination titer \>= 4 times the LLOQ; - if pre-vaccination titer is \>= LLOQ, then a post-vaccination titer \>= 4 times the pre-vaccination titer, where pre-vaccination titer=pre-4th dose titers (Day 301). This outcome measure evaluated immune response to the rMenB+OMV NZ vaccine only, hence it was not applicable to the Placebo+PCV group.

Time frame:
At Day 331 (1 month after the fourth vaccination) relative to Day 301 (pre-fourth vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With 4-fold Rise in hSBA Titers for Each of the Serogroup B Test Strains M14459 (fHbp), 96217 (NadA), NZ98/254 (PorA P1.4), and M13520 (NHBA)
Percentage of participantsMenB+PCV Group
M14459 (fHbp), Day 33172.0 (67.5 to 76.1)
96217 (NadA), Day 33194.8 (92.2 to 96.7)
M13520 (NHBA), Day 33136.1 (31.8 to 40.7)
NZ98/254 (PorA P1.4), Day 33154.2 (49.5 to 58.9)
SecondaryPercentage of Participants With Anti-HBs Antibody Concentrations >= 100 mIU/mL
Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-HBs Antibody Concentrations >= 100 mIU/mL
Percentage of participantsMenB+PCV GroupPlacebo+PCV Group
Percentage of Participants With Anti-HBs Antibody Concentrations >= 100 mIU/mL98.1 (93.3 to 99.8)96.4 (91.7 to 98.8)
SecondaryGMCs for Anti-HBsAg Antibodies
Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Geometric mean · mIU/mL
GMCs for Anti-HBsAg Antibodies
mIU/mLMenB+PCV GroupPlacebo+PCV Group
GMCs for Anti-HBsAg Antibodies2201.0 (1554.7 to 3116.0)2404.8 (1803.1 to 3207.3)
SecondaryPercentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 1 IU/mL
Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-diphtheria and Anti-tetanus Antibody Concentrations >= 1 IU/mL
Percentage of participantsMenB+PCV GroupPlacebo+PCV Group
Tetanus Toxoid67.0 (60.4 to 73.1)69.2 (61.0 to 76.7)
Diphtheria Toxoid40.0 (33.5 to 46.8)55.1 (46.4 to 63.7)
SecondaryGMCs for Anti-diphtheria and Anti-tetanus Antibodies
Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Geometric mean · IU/mL
GMCs for Anti-diphtheria and Anti-tetanus Antibodies
IU/mLMenB+PCV GroupPlacebo+PCV Group
Tetanus Toxoid1.5 (1.3 to 1.8)1.6 (1.3 to 1.9)
Diphtheria Toxoid0.9 (0.8 to 1.1)1.2 (1.0 to 1.5)
SecondaryPercentage of Participants With Anti-polio Type 1, 2 and 3 Neutralization Antibody Titers >= 8
Time frame:
At Day 151 (1 month after the third vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With Anti-polio Type 1, 2 and 3 Neutralization Antibody Titers >= 8
Percentage of participantsMenB+PCV GroupPlacebo+PCV Group
Polio 1100 (96.4 to 100)100 (97.0 to 100)
Polio 299.1 (94.9 to 100)100 (96.9 to 100)
Polio 3100 (96.3 to 100)99.1 (95.1 to 100)
SecondaryPercentage of Participants With Seroresponse for Anti-Varicella (VV), Anti-measles Virus, Anti-mumps Virus and Anti-rubella Virus Antibodies

Seroresponse is defined as post-vaccination anti-VZV virus, anti-measles virus, anti-mumps virus and anti-rubella virus antibody concentration \>= a protective threshold among participants who were seronegative (antibody concentration \< assay cut-off) before vaccination.

Time frame:
At Day 331 (1 month after the fourth vaccination)
Reported as:
Number · Percentage of participants
Percentage of Participants With Seroresponse for Anti-Varicella (VV), Anti-measles Virus, Anti-mumps Virus and Anti-rubella Virus Antibodies
Percentage of participantsMenB+PCV GroupPlacebo+PCV Group
Mumps81.6 (77.2 to 85.5)85.9 (80.2 to 90.4)
Measles94.8 (91.9 to 96.9)97.9 (94.7 to 99.4)
Rubella86.4 (82.3 to 89.8)83.9 (78.1 to 88.7)
VZV gE97.3 (95.0 to 98.7)97.5 (94.3 to 99.2)

Adverse events

Collected over Solicited AEs: Day 1 to Day 7 post each vaccination, Solicited systemic AEs of salivary gland swelling, fever and rash: Day 1 to Day 30 post fourth vaccination; Unsolicited AEs: Day 1 to Day 30 post each vaccination. All-cause mortality, SAEs, AEs leading to withdrawal, AESIs and MAAEs: For participants not reaching Day 481 by Protocol Amendment 7: first vaccination (Day 1) to Day 481, for participants past Day 481 by the amendment: first vaccination (Day 1) to Day 661. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MenB+PCV Group0/781 (0%)35/781 (4.5%)771/781 (98.7%)
Placebo+PCV Group0/403 (0%)19/403 (4.7%)389/403 (96.5%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventMenB+PCV GroupPlacebo+PCV Group
BronchiolitisInfections and infestations4/7812/403
Respiratory syncytial virus bronchiolitisInfections and infestations3/7812/403
Respiratory syncytial virus infectionInfections and infestations2/7812/403
GastroenteritisInfections and infestations3/7811/403
Febrile convulsionNervous system disorders3/7811/403
PyrexiaGeneral disorders2/7810/403
InfluenzaInfections and infestations2/7811/403
PneumoniaInfections and infestations2/7811/403
SeizureNervous system disorders2/7810/403
LymphadenitisBlood and lymphatic system disorders0/7811/403
Most frequent other events
Showing 10 of 304
Most frequent other events
EventMenB+PCV GroupPlacebo+PCV Group
IrritabilityPsychiatric disorders713/781330/403
SomnolenceNervous system disorders681/781319/403
Administration site painGeneral disorders582/781201/403
HypophagiaMetabolism and nutrition disorders543/781216/403
PyrexiaGeneral disorders521/781172/403
Administration site indurationGeneral disorders480/781180/403
Administration site erythemaGeneral disorders460/781170/403
CryingGeneral disorders432/781163/403
DiarrhoeaGastrointestinal disorders334/781178/403
Administration site swellingGeneral disorders322/781122/403

Baseline characteristics

Age, Continuous
Age, Continuous(Weeks)MenB+PCV GroupPlacebo+PCV GroupTotal
Mean8.6 ± 1.08.8 ± 1.08.7 ± 1.0
Sex: Female, Male
Sex: Female, Male(Participants)MenB+PCV GroupPlacebo+PCV GroupTotal
Female380196576
Male401207608
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)MenB+PCV GroupPlacebo+PCV GroupTotal
American Indian or Alaska Native17421
Asian392160
Black or African American8433117
Native Hawaiian or Other Pacific Islander314
White531288819
Other (Not specified)10756163
08

Study locations

57 sites
  • GSK Investigational Site
    Birmingham, Alabama 35205, United States
  • GSK Investigational Site
    Fayetteville, Arkansas 72703, United States
  • GSK Investigational Site
    Jonesboro, Arkansas 72401, United States
  • GSK Investigational Site
    Anaheim, California 92804, United States
  • GSK Investigational Site
    Oakland, California 94611, United States
  • GSK Investigational Site
    Roseville, California 95661, United States
  • GSK Investigational Site
    Walnut Creek, California 94596, United States
  • GSK Investigational Site
    West Covina, California 91790, United States
  • GSK Investigational Site
    Lake Mary, Florida 32746, United States
  • GSK Investigational Site
    Miami, Florida 33142, United States
  • GSK Investigational Site
    Tampa, Florida 33613, United States
  • GSK Investigational Site
    Nampa, Idaho 83686, United States
  • GSK Investigational Site
    Nampa, Idaho 83702, United States
  • GSK Investigational Site
    Newton, Kansas 67114, United States
  • GSK Investigational Site
    Topeka, Kansas 66604, United States
  • GSK Investigational Site
    Bardstown, Kentucky 40004, United States
  • GSK Investigational Site
    Louisville, Kentucky 40202, United States
  • GSK Investigational Site
    Louisville, Kentucky 40207, United States
  • GSK Investigational Site
    Louisville, Kentucky 40291, United States
  • GSK Investigational Site
    Baltimore, Maryland 21021, United States
  • GSK Investigational Site
    Fall River, Massachusetts 02721, United States
  • GSK Investigational Site
    Bingham Farms, Michigan 48025, United States
  • GSK Investigational Site
    Kansas City, Missouri 64108, United States
  • GSK Investigational Site
    Lincoln, Nebraska 68516, United States
  • GSK Investigational Site
    Omaha, Nebraska 68128, United States
  • GSK Investigational Site
    Liverpool, New York 13090, United States
  • GSK Investigational Site
    Syracuse, New York 13210, United States
  • GSK Investigational Site
    Boone, North Carolina 28607, United States
  • GSK Investigational Site
    Raleigh, North Carolina 27609, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45245, United States
  • GSK Investigational Site
    Dayton, Ohio 45406, United States
  • GSK Investigational Site
    Dayton, Ohio 45414, United States
  • GSK Investigational Site
    Fairfield, Ohio 45014, United States
  • GSK Investigational Site
    South Euclid, Ohio 44121, United States
  • GSK Investigational Site
    Hermitage, Pennsylvania 16148, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15224, United States
  • GSK Investigational Site
    Charleston, South Carolina 29406, United States
  • GSK Investigational Site
    Sioux Falls, South Dakota 57105, United States
  • GSK Investigational Site
    Clarksville, Tennessee 37040, United States
  • GSK Investigational Site
    Kingsport, Tennessee 37660, United States
  • GSK Investigational Site
    Beaumont, Texas 77706, United States
  • GSK Investigational Site
    Bryan, Texas 77802, United States
  • GSK Investigational Site
    Edinburg, Texas 78504, United States
  • GSK Investigational Site
    Houston, Texas 77065, United States
  • GSK Investigational Site
    Houston, Texas 77090, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    San Antonio, Texas 78244, United States
  • GSK Investigational Site
    Layton, Utah 84041, United States
  • GSK Investigational Site
    Orem, Utah 84057, United States
  • GSK Investigational Site
    Provo, Utah 84604, United States
  • GSK Investigational Site
    Roy, Utah 84067, United States
  • GSK Investigational Site
    Salt Lake City, Utah 84121, United States
  • GSK Investigational Site
    Syracuse, Utah 84075, United States
  • GSK Investigational Site
    Richmond, Virginia 23298, United States
  • GSK Investigational Site
    Spokane, Washington 99202, United States
  • GSK Investigational Site
    Marshfield, Wisconsin 54449, United States
  • GSK Investigational Site
    San Juan, 00907, Puerto Rico
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2018 to primary completion in Dec 2024, 77 months.

Results were first posted in Feb 2026, 1 year 1 month after primary completion.

Of 46 industry-sponsored phase 3 interventional studies under Meningococcal Infections, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 40. This study's 77 months is above that.

Counting every sponsor, half of 46 studies reached it within 15 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2018
First posted
Aug 8, 2018
StartActual
Jul 27, 2018
Primary completionActual
Dec 27, 2024
CompletionActual
Dec 27, 2024
Results first posted
Feb 10, 2026
Last update
Aug 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03621670
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Aug 8, 2018
Start date
Jul 27, 2018
Primary completion
Dec 27, 2024
Completion
Dec 27, 2024
Results posted
Feb 10, 2026
Last update
Aug 20, 2026

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion